Tolvaptan delays disease progression in polycystic kidney disease patients

1. 1.Tolvaptan delayed the decline of estimated glomerular filtration rate (eGFR) and total kidney volume (TKV) in ADPKD patients when compared to the placebo group.
2. 2.The use of tolvaptan delayed TKV progression in different-month subgroups.
3. 3.Tolvaptan reduced renal pain and hematuria events in ADPKD patients.
4. 4.The prevalence of thirst and nocturia events was increased in the tolvaptan group compared to the placebo group.
5. 5.Tolvaptan reduced renal pain and hematuria events in ADPKD patients.

Tolvaptan is currently the only medication approved by the US Food and Drug Administration (FDA) to treat ADPKD, as it has been shown to slow the progression of the disease by reducing the growth of kidney cysts.

The researchers added that “The findings of this meta-analysis provide further evidence of the efficacy and safety of tolvaptan in the treatment of ADPKD, and may help to inform clinical decision-making regarding the use of this medication.”

Reference:

Li, X., Li, W., Li, Y., Dong, C., & Zhu, P. (2023). The safety and efficacy of tolvaptan in the treatment of patients with autosomal dominant polycystic kidney disease: A systematic review and meta-analysis. Nefrologia. https://doi.org/10.1016/j.nefroe.2023.04.002